AIM HIGH: Niacin Plus Statin to Prevent Vascular Events.

Trial Profile

AIM HIGH: Niacin Plus Statin to Prevent Vascular Events.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Niacin (Primary) ; Ezetimibe; Simvastatin
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Acronyms AIM-HIGH
  • Sponsors Axio Research Corporation
  • Most Recent Events

    • 16 Nov 2016 Post-hoc analysis results presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 29 Mar 2016 Results published in the American Journal of Medicine
    • 20 Nov 2013 Results after an additional 1.1 years following study discontinuation presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top